康力欣胶囊联合化疗治疗晚期非小细胞肺癌的临床观察
|
摘要
目的探讨康力欣胶囊联合化疗治疗晚期非小细胞肺癌的临床疗效。方法回顾性分析2016年7月至2017年12月晚期非小细胞肺癌患者46例,其中23例单纯使用化疗,作为对照组;另23例在化疗的基础上加用康力欣胶囊(1次1g,1日3次),作为治疗组。观察两组患者的近期疗效、不良反应及免疫功能的变化。结果治疗组和对照组治疗结束后总有效率分别为95.65%,91.30%,(P>0.05);治疗组患者3～4级白细胞下降、血红蛋白减少、胃肠道反应及肝肾功损害的发生率显著低于对照组,(P<0.05);治疗结束后,治疗组CD3~+、CD4~+、CD4~+/CD8~+较治疗前升高,CD8~+较治疗前下降(P<0.05);对照组CD3~+较治疗前下降(P<0.05);治疗后治疗组CD3~+、CD4~+、CD4~+/CD8~+均明显高于对照组,CD8~+低于对照组,差异均有统计学意义(P<0.05)。结论应用康力欣胶囊联合化疗可提高晚期非小细胞肺癌患者疗效,降低不良反应,提高免疫功能。
OBJECTIVE To study the KangLiXin capsule MDT the clinical curative effect in the treatment of advanced non-small cell lung cancer.METHODS A retrospective analysis was conduct on 46 patients with non-small-cell lung cancer(NSCLC) from 2016 in late July to December 2017.23 cases receive simple use of chemotherapy as control group,other 23 cases on the basis of chemotherapy combined with KangLiXin capsule(1 g,tid) as the treatment group.Observing the recent curative effect,adverse reactions and changes of immune function of two groups.RESULTS The total effective rate of treatment group and control group were 95.65% and 91.30% after treatment(P>0.05);the side effect of treatment group was significantly lower than control group(P<0.05);After treatment,the treatment group(CD3~+,CD4~+,CD4~+/CD8~+ was higher,the CD8~+ before the treatment decreased(P<0.05);The control group of CD3~+ down(P<0.05);compared with before treatment Treatment group after treatment of CD3~+,CD4~+,CD4~+/CD8~+ was significantly higher than the control group,CD8~+ is lower than the control group,the difference had statistical significance(P<0.05).CONCLUSION The application of KangLiXin capsule combined with chemotherapy in the treatment of locally advanced non-small cell lung cancer patients can improve the curative effect,reduce adverse reaction,improve the patient′s immune function.
OBJECTIVE To study the KangLiXin capsule MDT the clinical curative effect in the treatment of advanced non-small cell lung cancer.METHODS A retrospective analysis was conduct on 46 patients with non-small-cell lung cancer(NSCLC) from 2016 in late July to December 2017.23 cases receive simple use of chemotherapy as control group,other 23 cases on the basis of chemotherapy combined with KangLiXin capsule(1 g,tid) as the treatment group.Observing the recent curative effect,adverse reactions and changes of immune function of two groups.RESULTS The total effective rate of treatment group and control group were 95.65% and 91.30% after treatment(P>0.05);the side effect of treatment group was significantly lower than control group(P<0.05);After treatment,the treatment group(CD3~+,CD4~+,CD4~+/CD8~+ was higher,the CD8~+ before the treatment decreased(P<0.05);The control group of CD3~+ down(P<0.05);compared with before treatment Treatment group after treatment of CD3~+,CD4~+,CD4~+/CD8~+ was significantly higher than the control group,CD8~+ is lower than the control group,the difference had statistical significance(P<0.05).CONCLUSION The application of KangLiXin capsule combined with chemotherapy in the treatment of locally advanced non-small cell lung cancer patients can improve the curative effect,reduce adverse reaction,improve the patient′s immune function.
引文
[1]Siegel R L,Miller K D,Jemal A.Cancer statistics,2016[J].Ca A Cancer Journal for Clinicians,2015,65(1):5.
[2]温先敏,杨缅南,段为钢,等.康力欣胶囊抗肿瘤活性的实验研究[J].云南中医中药杂志,2009,30(1):48-49.
[3]严虹霞,杨广文,刘如良,等.艾迪注射液联合化疗对肺癌患者免疫功能的影响[J].中国药物与临床,2012,12(9):1123-1124.
[4]郭利群,郭利华.康力欣胶囊治疗中晚期恶性肿瘤临床疗效观察[J].中医临床研究,2015(20):21-23.
[5]温先敏,杨缅南,段为钢,等.康力欣胶囊对小鼠免疫功能的促进作用[J].云南中医中药杂志,2008,29(9):45-46.
[6]张锦英,朱陵君,卢凯华,等.非小细胞肺癌患者化疗前后外周血T淋巴细胞亚群的变化[J].现代生物医学进展,2012,12(35):6814-6818.
[7]Boettler T,Spangenberg H C,Neumannhaefelin C,et al.T Cells with a CD4+ CD25+ Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8+ T Cells during Chronic Hepatitis C Virus Infection[J].Journal of Virology,2005,79(12):7860.
[8]Bolacchi F,Sinistro A,Ciaprini C,et al.Increased hepatitis C virus (HCV)‐specific CD4+ CD25+ regulatory T lymphocytes and reduced HCV‐specific CD4+ T cell response in HCV infected patients with normal versus abnormal alanine aminotransferase levels[J].Clinical & Experimental Immunology,2006,144(2):188-96.
[9]任秀红,刘莉,刘平平,等.恶性肿瘤患者T细胞亚群变化及其与肿瘤分期的关系[J].第三军医大学学报,2006,28(18):1906-1908.
[10]张景欣,马明.香菇多糖注射液对恶性肿瘤患者T淋巴细胞亚群及NK细胞的影响[J].中医药学报,2015,(4):116-118.
[2]温先敏,杨缅南,段为钢,等.康力欣胶囊抗肿瘤活性的实验研究[J].云南中医中药杂志,2009,30(1):48-49.
[3]严虹霞,杨广文,刘如良,等.艾迪注射液联合化疗对肺癌患者免疫功能的影响[J].中国药物与临床,2012,12(9):1123-1124.
[4]郭利群,郭利华.康力欣胶囊治疗中晚期恶性肿瘤临床疗效观察[J].中医临床研究,2015(20):21-23.
[5]温先敏,杨缅南,段为钢,等.康力欣胶囊对小鼠免疫功能的促进作用[J].云南中医中药杂志,2008,29(9):45-46.
[6]张锦英,朱陵君,卢凯华,等.非小细胞肺癌患者化疗前后外周血T淋巴细胞亚群的变化[J].现代生物医学进展,2012,12(35):6814-6818.
[7]Boettler T,Spangenberg H C,Neumannhaefelin C,et al.T Cells with a CD4+ CD25+ Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8+ T Cells during Chronic Hepatitis C Virus Infection[J].Journal of Virology,2005,79(12):7860.
[8]Bolacchi F,Sinistro A,Ciaprini C,et al.Increased hepatitis C virus (HCV)‐specific CD4+ CD25+ regulatory T lymphocytes and reduced HCV‐specific CD4+ T cell response in HCV infected patients with normal versus abnormal alanine aminotransferase levels[J].Clinical & Experimental Immunology,2006,144(2):188-96.
[9]任秀红,刘莉,刘平平,等.恶性肿瘤患者T细胞亚群变化及其与肿瘤分期的关系[J].第三军医大学学报,2006,28(18):1906-1908.
[10]张景欣,马明.香菇多糖注射液对恶性肿瘤患者T淋巴细胞亚群及NK细胞的影响[J].中医药学报,2015,(4):116-118.